Ricerca avanzata

Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2016 Settembre;41(3) > Minerva Endocrinologica 2016 Settembre;41(3):324-40

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

 

Minerva Endocrinologica 2016 Settembre;41(3):324-40

MEDICAL TREATMENT OF PITUITARY TUMORS 

 REVIEWS

Medical treatment of Cushing’s Disease

Daniel CUEVAS-RAMOS 1, Maria FLESERIU 2

1 Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico City, Mexico; 2 Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA

Cushing’s Syndrome (CS) is a serious endocrine disease that results from the adverse clinical consequences of chronic exposure to high levels of glucocorticoids. Most patients with endogenous CS have an adrenocorticotropin (ACTH)-secreting pituitary corticotroph adenoma, i.e. Cushing’s Disease (CD). The first-line therapy for CD is transsphenoidal pituitary surgery. If tumor removal is incomplete or unsuccessful, persistent hypercortisolism will require further treatment. Repeat surgery, medical therapy, radiation and bilateral adrenalectomy are all second line therapy options; however, medical therapy can be also used as first line therapy in patients who cannot undergo surgery, or to decrease cortisol values and/or improve co-morbidities. Medications used in the treatment of CD, classified into three groups: pituitary directed drugs, adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers, are reviewed. Future ‘on the horizon’ treatment options are also discussed.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina